Atopic Dermatitis - The Dermatology Digest

Monthly Maintenance Doses of Lebrikizumab Produce Long-lasting Results in AD

September 25, 2024

Phase 3 Results: Roflumilast Cream 0.15% (Zoryve, Arcutis) Hits Multiple Efficacy Endpoints in AD

September 19, 2024

Business News: Organon to Buy Dermavant including Tapinarof Cream, 1%(Vtama)

September 18, 2024

Newly Approved Lebrikizumab Shows Promise in Patients With Darker Skin and AD

September 17, 2024

Tralokinumab-ldrm (Adbry) Autoinjector Now Available for the Treatment of Adults With Moderate-to-Severe AD in the U.S.

September 17, 2024

BREAKING NEWS: U.S. FDA Approves Lilly’s Ebglyss (Lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe AD

September 13, 2024

Advertisement

Latest Issue

Latest Supplements

Advertisement

Digital Edition Archive

Advertisement